Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Chronic Pancreatitis II: Collaborative Care01:29

Chronic Pancreatitis II: Collaborative Care

435
The management of chronic pancreatitis is multifaceted, involving a comprehensive approach that includes thorough assessment, diagnostic testing, and a variety of management strategies.
Assessment:
435
Inflammatory Bowel Disease IV: Pharmacological Management01:29

Inflammatory Bowel Disease IV: Pharmacological Management

860
Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
860
Chronic Bowel Disorders: Introduction01:17

Chronic Bowel Disorders: Introduction

853
Chronic bowel diseases are a group of long-term conditions affecting the digestive tract, characterized by inflammation and damage to the gut lining. These conditions primarily include irritable bowel syndrome and inflammatory bowel disease.
Irritable Bowel Syndrome (IBS) is a common disorder affecting the gastrointestinal tract. The distinctive feature is recurrent abdominal pain associated with altered bowel movements, manifesting as constipation, diarrhea, or fluctuating between both. The...
853
Acute Pancreatitis II: Clinical Manifestations and Management01:30

Acute Pancreatitis II: Clinical Manifestations and Management

960
Acute pancreatitis presents a complex medical emergency characterized by rapid onset inflammation of the pancreas, demanding timely diagnosis and management to prevent complications. The condition primarily manifests through severe upper abdominal pain that often radiates to the back. This pain intensifies following the consumption of fatty foods. Accompanying symptoms such as nausea, vomiting, abdominal distention, fever, dyspnea, cyanosis, and jaundice can vary in intensity but significantly...
960
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

9.0K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
9.0K
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF01:24

Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF

658
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...
658

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

A Journey Through Chronotype Changes in University Students.

Journal of biological rhythms·2026
Same author

Prevention of Portal Hypertension Complications Beyond Primary TIPS Indication Is Independent of Endoprosthesis Under-Dilation.

Liver international : official journal of the International Association for the Study of the Liver·2026
Same author

New Treatment Options for MASLD Patients with Type 2 Diabetes.

Life (Basel, Switzerland)·2026
Same author

Shunt magnitude is a key determinant of overt hepatic encephalopathy in patients undergoing TIPS.

JHEP reports : innovation in hepatology·2026
Same author

Sex Hormones and the Liver: Implications for Disease Progression and Hormonal Therapy.

Liver international : official journal of the International Association for the Study of the Liver·2026
Same author

Authors' Reply to "Reconsidering the Plasma Ammonia Levels in Overt Hepatic Encephalopathy".

Liver international : official journal of the International Association for the Study of the Liver·2025

Related Experiment Video

Updated: Feb 27, 2026

Partial Bile Duct Ligation in the Mouse: A Controlled Model of Localized Obstructive Cholestasis
04:38

Partial Bile Duct Ligation in the Mouse: A Controlled Model of Localized Obstructive Cholestasis

Published on: March 28, 2018

16.6K

Primary biliary cholangitis: Old and novel therapy.

Annarosa Floreani1, Chiara Mangini1

  • 1Department of Surgery, Oncology and Gastroenterology, University of Padova, Italy.

European Journal of Internal Medicine
|July 4, 2017
PubMed
Summary
This summary is machine-generated.

Primary biliary cholangitis (PBC) treatments are evolving beyond ursodeoxycholic acid (UDCA). Obeticholic acid (OCA) shows promise, with about 50% of non-responders achieving significant biomarker improvements.

Keywords:
BudesonideFibratesObeticholic acidPrimary biliary cholangitisPrimary biliary cirrhosisRituximabTreatmentUrsodeoxycholic acidUstekinumab

More Related Videos

Laparoscopic Common Bile Duct Exploration in Patients with a Previous History of Biliary Tract Surgery
07:36

Laparoscopic Common Bile Duct Exploration in Patients with a Previous History of Biliary Tract Surgery

Published on: February 10, 2023

2.5K

Related Experiment Videos

Last Updated: Feb 27, 2026

Partial Bile Duct Ligation in the Mouse: A Controlled Model of Localized Obstructive Cholestasis
04:38

Partial Bile Duct Ligation in the Mouse: A Controlled Model of Localized Obstructive Cholestasis

Published on: March 28, 2018

16.6K
Laparoscopic Common Bile Duct Exploration in Patients with a Previous History of Biliary Tract Surgery
07:36

Laparoscopic Common Bile Duct Exploration in Patients with a Previous History of Biliary Tract Surgery

Published on: February 10, 2023

2.5K

Area of Science:

  • Hepatology
  • Gastroenterology
  • Pharmacology

Background:

  • Primary biliary cholangitis (PBC) is a chronic liver disease.
  • Ursodeoxycholic acid (UDCA) is the primary treatment, but 30-40% of patients show inadequate response.
  • Emerging therapies are crucial for non-responders and intolerant patients.

Purpose of the Study:

  • To evaluate the efficacy of obeticholic acid (OCA) as a second-line treatment for PBC.
  • To assess OCA's impact on serum alkaline phosphatase (ALP) levels, a key prognostic marker.
  • To explore new therapeutic targets for PBC based on pathophysiology.

Main Methods:

  • A randomized, double-blind, phase 3 study comparing OCA (at specified doses) to placebo.
  • Monitoring of serum alkaline phosphatase levels as a primary efficacy endpoint.
  • Inclusion of patients who are non-responders or intolerant to UDCA.

Main Results:

  • Approximately 50% of patients treated with OCA achieved significant reduction in serum alkaline phosphatase.
  • OCA demonstrated efficacy in a patient population with limited treatment options.
  • Serum ALP reduction is a validated predictor of PBC progression, liver transplantation, and mortality.

Conclusions:

  • Obeticholic acid (OCA) represents a significant advancement in PBC treatment for non-responders to UDCA.
  • Further research into novel therapeutic targets is ongoing, offering new hope for PBC patients.
  • The development of new agents signifies a shift towards personalized and targeted PBC therapies.